Videos

Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.

Experts share operational challenges and patient care implications of the Inflation Reduction Act's (IRA) drug pricing reforms.

Panelists discuss how the initiation of statin therapy requires careful consideration of contraindications and patient-specific factors, particularly in those with liver disease, renal impairment, or advanced age, while noting evolving treatment patterns toward more intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapies based on individualized risk assessment.

Panelists discuss how statin therapy for primary prevention requires careful consideration of cardiovascular risk factors against potential adverse effects such as myalgia and liver abnormalities, generally favoring treatment when the calculated 10-year atherosclerotic cardiovascular disease [ASCVD] risk exceeds 7.5% to10% and adjusting recommendations based on individual patient factors including age, comorbidities, and preferences.

Pharmacists play a crucial role in advancing biosimilar adoption through targeted education, addressing misconceptions about safety and efficacy.

Logan Schneider, MD, explains the latest findings on narcolepsy and idiopathic hypersomnia treatments, highlighting patient experiences and sleep architecture improvements.

A panelist discusses how combining therapies for EGFR-positive non–small cell lung cancer (NSCLC) increases both benefits (improved progression-free survival, response rates, and duration of response) and adverse effects, emphasizing that treatment selection should consider patient-specific factors like central nervous system (CNS) metastases, performance status, treatment aggressiveness preferences, and real-world limitations where patients often differ from clinical trial populations in terms of organ dysfunction, concomitant medications, and previous treatments.

A panelist discusses how recent clinical trials for EGFR-positive non–small cell lung cancer (NSCLC) have expanded treatment options beyond single oral agents, with studies like FLAURA2, MARIPOSA, and PAPILLON demonstrating significant improvements in progression-free survival for combination therapies such as osimertinib plus chemotherapy and amivantamab plus lazertinib, though these combinations often come with higher rates of toxicity, discontinuation, and adverse effects compared to monotherapies.

Ginger Blackmon, PharmD, explains how NCODA’s Positive Quality Interventions (PQIs) help improve oncology care by guiding best practices, supporting teamwork, and streamlining workflows.

Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discussed concerns the association has with the implementation of the Medicare Drug Price Negotiation Plan

Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discusses concerns about the implementation of the MDPNP.

Philip Kuball, MD, neurology resident at NYU Langone Health, highlights the integral role of pharmacists in monitoring patient eligibility, managing dosing schedules, and ensuring safe medication interactions for lecanemab treatment in Alzheimer disease.

Lauren B. Krupp, MD, FAAN, provides comprehensive guidance on treating pediatric multiple sclerosis, emphasizing early intervention, high-efficacy therapies, and holistic family support.

A panelist discusses how waiting for molecular testing results before initiating treatment for non–small cell lung cancer (NSCLC) is crucial because patients with EGFR mutations can avoid chemotherapy and immunotherapy in favor of targeted oral agents like osimertinib, which offer survival benefits with minimal toxicity compared to traditional treatments, while premature immunotherapy could cause severe immune-related adverse events that might preclude later use of more appropriate targeted therapies.

A panelist discusses how non–small cell lung cancer presents significant treatment challenges due to its prevalence, high mortality rate, poor 5-year survival outcomes, and the difficulty of managing patients with advanced disease who often have poor performance status and multiple metastases, emphasizing the importance of pharmacist involvement for proper dosing, growth factor support, and comprehensive patient education about chemotherapy.

UPMC enhances care for patients with heart failure through integrated pharmacy and cardiology team collaboration.

A recent analysis from NCPA showed potential weekly cash flow shortfalls for pharmacies and annual revenue losses.

Iman Ahmed, PharmD, BCOP shared key insights about how social determinants of health impact treatment access and outcomes for patients with leukemia.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, shared insight from the HOPA Annual Meeting 2025.

Arefa Bacchus, PharmD shared key insights about the use of POMP therapy in patients with acute lymphoblastic leukemia (ALL).

Monica Sawiris, PharmD, said there were noticeable differences in toxicities between each regimen.

Erin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.

Shelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.

Panelists discuss how evolving clinical guidelines for intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapies have shaped personalized treatment approaches through risk stratification, with different targets for primary vs secondary prevention and consideration of genetic factors when determining appropriate statin intensity.

Panelists discuss how cardiology practice has evolved toward more aggressive low-density lipoprotein cholesterol (LDL-C)–lowering strategies across specialties, with current guidelines generally recommending targets below 70 mg/dL for high-risk patients and even lower thresholds (below 55 mg/dL) for very high-risk individuals, though these targets require personalization based on age, comorbidities such as diabetes and hypertension, and other cardiovascular risk factors.